![]() The TYM has the added advantage of being self-administered and requiring minimal supervision. A subsequent study using a Japanese version of the test highlighted its potential for use as a screening tool for aMCI, reporting high sensitivity (76%) and specificity (74%). The developers of TYM reported that it had very high sensitivity (93%) and high specificity (86%) for discriminating between people with and without mild Alzheimer's disease. The developers of which is a brief, interviewer-administered memory task, reported it to have very high sensitivity (96%) and high specificity (70%–79%) for discriminating between people with aMCI and healthy controls. The Memory Alteration Test and the Test Your Memory (TYM) test were selected for investigation in this study. The present study aimed to address this limitation by assessing the validity of two brief cognitive tests in a cohort of participants all recruited from the community, without prior knowledge of their cognitive status, thereby reducing the risk of bias in the assessment process. This exposed the studies to risk of unblinding of the patient assessment process and potentially exaggerated diagnostic accuracy. Most studies selected patients with known aMCI from memory clinics and compared their performance on the test under evaluation with an opportunistically recruited group of people assumed to have no cognitive impairment. Several of these cognitive tests demonstrated promising diagnostic test accuracy, although most studies were found to be at a high risk of bias due to the method of participant selection used. They could also be applied by researchers to find suitable participants for enrollment into studies of candidate interventions targeted at this early stage of cognitive decline.Ī recent systematic review found that over 40 brief cognitive tests have been developed and tested to identify people with aMCI. These would provide a useful resource to busy primary health care staff who are encouraged, as stated in UK national guidance, to refer people who show signs of MCI for further assessment by memory assessment services to aid early identification of dementia. There is a need for simple, quick, and sensitive cognitive tests that will provide a more efficient way of identifying people with aMCI. Īmnestic MCI is however largely unrecognized in primary care as its diagnosis depends on complex neuropsychological assessment methods not usually available in this setting. It has been suggested that it may be more effective to target interventions at people in this predementia phase of AD, before the progressive disease is established. The amnestic form of MCI (aMCI), where the predominant symptom is memory impairment, is associated with elevated rates of conversion to Alzheimer's disease (AD). Mild cognitive impairment (MCI) has emerged as a term to capture the predementia phase of cognitive dysfunction and is defined as “cognitive decline greater than that expected for an individual's age and education level but that does not interfere notably with activities of daily life”. There has been a growing clinical and research interest in the early identification of people at risk of developing dementia.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |